Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome.
De Souza CA, Vigorito AC, Ruiz MA, Nucci M, Dulley FL, Funcke V, Tabak D, Azevedo AM, Byington R, Macedo MC, Saboya R, Penteado Aranha FJ, Oliveira GB, Zulli R, Martins Miranda EC, Azevedo WM, Lodi FM, Voltarelli JC, Simões BP, Colturato V, De Souza MP, Silla L, Bittencourt H, Piron-Ruiz L, Maiolino A, Gratwohl A, Pasquini R. De Souza CA, et al. Among authors: pasquini r. Haematologica. 2005 Feb;90(2):232-7. Haematologica. 2005. PMID: 15710577
Incidence of aplastic anemia and agranulocytosis in Latin America--the LATIN study.
Hamerschlak N, Maluf E, Pasquini R, Eluf-Neto J, Moreira FR, Cavalcanti AB, Okano IR, Falcão RP, Pita MT, Loggetto SR, Rosenfeld LG, Lorand-Metze IG. Hamerschlak N, et al. Among authors: pasquini r. Sao Paulo Med J. 2005 May 2;123(3):101-4. doi: 10.1590/s1516-31802005000300002. Epub 2005 Jul 8. Sao Paulo Med J. 2005. PMID: 16021270 Free PMC article.
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah N. Kantarjian H, et al. Among authors: pasquini r. Blood. 2007 Jun 15;109(12):5143-50. doi: 10.1182/blood-2006-11-056028. Epub 2007 Feb 22. Blood. 2007. PMID: 17317857 Free article. Clinical Trial.
Incidence and risk factors for agranulocytosis in Latin American countries--the Latin Study: a multicenter study.
Hamerschlak N, Maluf E, Biasi Cavalcanti A, Avezum Júnior A, Eluf-Neto J, Passeto Falcão R, Lorand-Metze IG, Goldenberg D, Leite Santana C, de Oliveira Werneck Rodrigues D, Nascimento da Motta Passos L, Oliveira de Miranda Coelho E, Tostes Pintão MC, Moraes de Souza H, Borbolla JR, Pasquini R. Hamerschlak N, et al. Among authors: pasquini r. Eur J Clin Pharmacol. 2008 Sep;64(9):921-9. doi: 10.1007/s00228-008-0513-7. Epub 2008 Jun 26. Eur J Clin Pharmacol. 2008. PMID: 18581105
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury HJ, Khoroshko N, Bradley-Garelik MB, Zhu C, Tallman MS. Kantarjian H, et al. Among authors: pasquini r. Blood. 2009 Jun 18;113(25):6322-9. doi: 10.1182/blood-2008-11-186817. Epub 2009 Apr 15. Blood. 2009. PMID: 19369231 Free PMC article. Clinical Trial.
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. Kantarjian H, et al. Among authors: pasquini r. Cancer. 2009 Sep 15;115(18):4136-47. doi: 10.1002/cncr.24504. Cancer. 2009. PMID: 19536906 Free PMC article. Clinical Trial.
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP. Cortes JE, et al. Among authors: pasquini r. J Clin Oncol. 2010 Jan 20;28(3):424-30. doi: 10.1200/JCO.2009.25.3724. Epub 2009 Dec 14. J Clin Oncol. 2010. PMID: 20008622 Free PMC article. Clinical Trial.
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M. Kantarjian H, et al. Among authors: pasquini r. N Engl J Med. 2010 Jun 17;362(24):2260-70. doi: 10.1056/NEJMoa1002315. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525995 Free article. Clinical Trial.
234 results